Prisca Chinonso Njoku

Prisca Chinonso Njoku

Auto-generated profile, based on publicly available information

Prisca Chinonso Njoku

Department of Biochemistry, University of Lagos, Yaba, Lagos State, Nigeria

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2023 in Research Square
Verified
Preprint
Open access
PDF file
OAOluwafemi Ojo Agosile
Oluwafemi Ojo Agosile
PNPrisca Chinonso Njoku
Prisca Chinonso Njoku
UOUgochukwu Oduwe
Ugochukwu Oduwe
AAAyokanmi Joseph Aremu
Ayokanmi Joseph Aremu
SFSunday Joseph Fajobi
Sunday Joseph Fajobi
EOEmmanuel Sunday Omirin
Emmanuel Sunday Omirin
More than 19 percent of all human cancer cases globally express mutant RAS proteins, which are the most frequently altered oncogenic proteins. Targeting cancer cells becomes difficult because these oncogenic proteins and cancer cells that are driven by Ras mutation show very aggressive traits. KRAS is the most expressed among the three isoforms of Ras mutation, which usually occur at position 12. KRAS G12C and KRAS G12D are common types of KRAS that have been proven difficult to target for many years. In recent times, many studies started to show that a lot of food spices possess strong anticancer properties that can target many cancer cells. Therefore, computational methods to access the anticancer properties of some selected compounds that are present in common food spices against KRAS G12C and KRAS G12D in their inactive GDP-bound state. These compounds were molecularly docked with standard drugs after their ADMET screening revealed their druglikeness. Chlorogenic acid and Rosmarinic acid displayed better binding affinity to the targets than all other drugs studied in this research. Molecular dynamics simulation was used to verify this compound's stability. Therefore, after extensive experimental effort, it is most likely that Rosmarinic acid would be effective as a KRAS G12C medicine.

28 August 2022 in Scientific African
Verified
Journal Article
Open access
AAAlfred Olaoluwa Akinlalu
Alfred Olaoluwa Akinlalu
PNPrisca Chinonso Njoku
Prisca Chinonso Njoku
CNChisom Vivian Nzekwe
Chisom Vivian Nzekwe
RORukayat Olayemi Oni
Rukayat Olayemi Oni
TFToyosi Fojude
Toyosi Fojude
Abolaji Samson OlagunjuAbolaji Samson Olagunju
Abolaji Samson Olagunju